Prof. Dr. Marc D. Piroth is a distinguished senior radiation oncologist renowned for his expertise in providing comprehensive cancer treatment through radiotherapy and chemotherapy procedures. His illustrious medical journey began with the pursuit of human medicine at Heinrich-Heine-University Düsseldorf, followed by studies in theology at Theolog. University Vallendar and a subsequent return to human medicine at the same university. Prof. Dr. Piroth's dedication to his medical career is highlighted by various pivotal roles and achievements. Commencing his internship at the Clinic for Radiotherapy and Radiological Oncology, Kliniken Maria Hilf, Mönchengladbach, in 1997, he embarked on a trajectory of professional growth. Noteworthy milestones include serving as a resident in the Department of Diagnostic Radiology at Marien-Hospital Düsseldorf and specializing in radiation therapy at Heidelberg University Hospital. Subsequently, he held positions as a resident in the Department of Radiation Oncology and Radiotherapy at the University Hospital of the RWTH Aachen, eventually attaining the role of Senior Physician at the same institution. Since 2013, Prof. Dr. Piroth has continued his impactful contributions as a Senior Physician in the Clinic for Radiation Therapy and Radio-Oncology at Helios University Hospital Wuppertal, concurrently holding the position of Medical Director of the Medical Care Center MVZ HELIOS Wuppertal GmbH since 2014. His academic accomplishments are equally impressive, including a doctorate in 1998 and licensing to practice medicine in 1999. Prof. Dr. Piroth earned his specialization in radiotherapy in 2003 and later achieved a habilitation in Radiotherapy at the Medical Faculty of the RWTH Aachen University in 2010. His research interests are evident in his work on implementing O-(2-[18F]fluoroethyl)L-tyrosine positron emission tomography (FET-PET) into the radiooncological concept of glioblastoma therapy, which formed the basis for his habilitation. Beyond his clinical and academic pursuits, Prof. Dr. Marc D. Piroth has garnered recognition for his contributions to palliative medicine, earning an additional designation in 2013. He was awarded an extraordinary professorship at the Faculty of Health, Department of Human Medicine at the University of Witten/Herdecke in 2017 and obtained a certificate in "Holistic Gynecological Oncology" from NATUM e.V. in 2017. Further, in 2019, he received a prestigious call to the Chair of Radiation Therapy and Radiooncology at the University of Witten/Herdecke. Adding to his extensive professional engagement, Prof. Dr. Piroth is an active member of various expert panels and working groups, contributing to the field of radiation oncology. Notably, he serves on the Expert Panel on Breast Cancer of the German Society for Radiation Oncology (DEGRO), acts as an expert for breast centers and gynecological cancer centers on behalf of the German Cancer Society, and participates in the Stereotaxy Working Group of DEGRO. Additionally, he holds the position of a member and auditor of the Medical Board of the North Rhine Medical Association. Prof. Dr. Marc D. Piroth's multifaceted contributions underscore his commitment to advancing the field of oncology and patient care.
Prof. Dr. Marc D. Piroth is celebrated for his expertise in advanced radiation oncology techniques. He specializes in Intensity Modulated Radiotherapy (IMRT), Volumetric Modulated Arc Therapy (VMAT), Image-Guided Radiotherapy (IGRT), stereotactic irradiation, and high-precision cancer treatments. His clinical practice at Helios University Hospital Wuppertal integrates these advanced methods to treat various cancers, including superficial tumors, using techniques such as intraoperative radiotherapy and combined radiochemotherapy. Prof. Piroth’s expertise also extends to palliative radiation and integrated oncological care, making him a popular and trusted figure in the German cancer treatment community. He’s particularly noted for applying FET-PET imaging in glioblastoma therapy, underscoring his commitment to personalized and high-impact treatment approaches. Through his involvement in key oncology working groups, he ensures his patients benefit from the latest evidence-based practices in cancer therapy.